---
document_datetime: 2025-12-02 05:01:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mabthera.html
document_name: mabthera.html
version: success
processing_time: 0.1487745
conversion_datetime: 2025-12-29 21:55:26.487755
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# MabThera

[RSS](/en/individual-human-medicine.xml/65879)

##### Authorised

This medicine is authorised for use in the European Union

rituximab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on MabThera](#news-on)
- [More information on MabThera](#more-information-on-mabthera-1129)
- [More information on MabThera](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

MabThera is a medicine used to treat the following blood cancers and inflammatory conditions:

- follicular lymphoma and diffuse large B cell non-Hodgkin's lymphoma (two types of non-Hodgkin's lymphoma, a blood cancer);
- chronic lymphocytic leukaemia (CLL, another blood cancer affecting white blood cells);
- severe rheumatoid arthritis (an inflammatory condition of the joints);
- two inflammatory conditions of blood vessels known as granulomatosis with polyangiitis (GPA or Wegener's granulomatosis) and microscopic polyangiitis (MPA);
- moderate to severe pemphigus vulgaris, an autoimmune disease characterised by widespread blistering and erosion of the skin and mucous membranes (the linings of internal organs). 'Autoimmune' means that the disease is caused by the immune system (the body's natural defences) attacking the body's own cells.

Depending on the condition it is used to treat, MabThera may be given on its own, or with chemotherapy, methotrexate or a corticosteroid.

MabThera contains the active substance rituximab.

Expand section

Collapse section

## How is MabThera used?

MabThera is given as an infusion (drip) into a vein. Patients with blood cancers can switch to an injection given under the skin after they have received one full dose of the infusion.

Before each infusion or injection, the patient should be given an antihistamine (to prevent allergic reactions) and an anti-pyretic (a medicine for fever). Depending on the condition being treated, the patients can also be given other medicines.

MabThera can only be obtained with a prescription. It should be given under the close supervision of an experienced healthcare professional and in an environment where facilities for resuscitating patients are immediately available.

For more information about using MabThera, see the package leaflet or contact your doctor or pharmacist.

## How does MabThera work?

The active substance in MabThera, rituximab, is a monoclonal antibody (a type of protein) designed to attach to a protein called CD20 present on B lymphocytes. When rituximab attaches to CD20, it causes the death of B lymphocytes, which helps in lymphoma and CLL (where B-lymphocytes have become cancerous) and in rheumatoid arthritis (where B lymphocytes are involved in joint inflammation). In GPA and MPA, destroying the B-lymphocytes lowers the production of antibodies thought to play an important role in attacking the blood vessels and causing inflammation.

## What benefits of MabThera have been shown in studies?

Studies show MabThera to be effective in treating all the conditions for which it is approved. Some results from the main studies on the benefits of MabThera are described below.

- In a follicular lymphoma study involving 322 patients, patients receiving MabThera in addition to chemotherapy lived for an average of 25.9 months without the disease coming back, compared with 6.7 months in those receiving chemotherapy alone.
- In a study of MabThera given on its own (203 patients), 48% of the patients with follicular lymphoma who had failed previous treatment responded to MabThera.
- In a maintenance study in patients whose follicular lymphoma had come back after previous treatment, patients who received MabThera alone lived for an average of 42.2 months without the disease getting worse, compared with 14.3 months in patients who did not receive the medicine. A maintenance study in previously untreated patients showed the likelihood for the disease to get worse was reduced by 50% for patients who received MabThera.
- In a study of 399 patients with diffuse large B-cell lymphoma, patients adding MabThera to chemotherapy lived for an average of 35 months without the disease getting worse or the need for a change in treatment, compared with 13 months in those receiving chemotherapy alone.
- In a study of 817 patients with CLL, patients who had not been treated before lived for an average of 39.8 months without their disease getting worse when they received MabThera in addition to chemotherapy, compared with 32.2 months in patients receiving chemotherapy alone. In patients whose disease had come back after previous treatment, those receiving MabThera lived for 30.6 months without their disease getting worse, compared with 20.6 months in those receiving chemotherapy alone.
- In a study of 517 patients with rheumatoid arthritis, MabThera was more effective than placebo: 51% of the patients receiving MabThera had an improvement in symptoms, compared with 18% of the patients receiving placebo.
- In a study of 198 patients with GPA or MPA, 64% of patients given MabThera were in complete remission after six months, compared with 55% given cyclophosphamide, a comparator medicine. A second study in 117 patients looked at the proportion of patients whose condition came back within 28 months. The study showed that only 5% of patients treated with MabThera had a relapse, compared with 29% of patients treated with azathioprine (another medicine used to treat GPA and MPA).
- In a study of 90 patients newly diagnosed with pemphigus, rituximab in combination with prednisone (a corticosteroid) was shown to be more effective than prednisone alone at clearing skin lesions. Following 2 years of treatment, 90% of patients treated with MabThera and short-term (up to 6 months) prednisone were in complete remission (meaning that skin and mucosa had healed and there were no new or old lesions) after stopping prednisone for 2 months or more, compared with 28% of patients treated with prednisone alone.

## What is the risk associated with MabThera?

The most common side effects with MabThera intravenous infusions are reactions related to the infusion (such as fever, chills and shivering) while most common serious side effects are infusion reactions, infections and heart-related problems. Similar side effects are seen when MabThera is injected under the skin, with the exception of reactions around the injections site (pain, swelling and rash), which occur more frequently with the skin injections. For the full list of side effects of MabThera, see the package leaflet.

MabThera must not be used in people who are hypersensitive (allergic) to rituximab, mouse proteins or any of the other ingredients or in patients with a severe infection or a severely weakened immune system. The formulation injected under the skin must also not be used in patients who are allergic to a substance called hyaluronidase.

Patients with rheumatoid arthritis, GPA, MPA or pemphigus must not receive MabThera if they have severe heart problems.

## Why is MabThera authorised in the EU?

The European Medicines Agency decided that MabThera's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of MabThera?

The company marketing MabThera will provide doctors and patients using the medicine for rheumatoid arthritis, GPA, MPA or pemphigus with educational material on the risk of infection including of a rare severe infection known as progressive multifocal leukoencephalopathy (PML). These patients are also to receive an alert card, which they are to carry at all times, instructing them to contact their doctor immediately if they experience symptoms of infection.

All doctors administering MabThera under the skin will also receive educational material to minimise the risk of improper use or errors.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of MabThera have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of MabThera are continuously monitored. Side effects reported with MabThera are carefully evaluated and any necessary action taken to protect patients.

## Other information about MabThera

MabThera received a marketing authorisation valid throughout the EU on 2 June 1998.

MabThera : EPAR - Medicine overview

Reference Number: EMA/580990/2020

English (EN) (151.7 KB - PDF)

**First published:** 30/10/2009

**Last updated:** 11/12/2020

[View](/en/documents/overview/mabthera-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-129)

български (BG) (163.74 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/bg/documents/overview/mabthera-epar-medicine-overview_bg.pdf)

español (ES) (138.85 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/es/documents/overview/mabthera-epar-medicine-overview_es.pdf)

čeština (CS) (164.79 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/cs/documents/overview/mabthera-epar-medicine-overview_cs.pdf)

dansk (DA) (137.98 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/da/documents/overview/mabthera-epar-medicine-overview_da.pdf)

Deutsch (DE) (142.03 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/de/documents/overview/mabthera-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.53 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/et/documents/overview/mabthera-epar-medicine-overview_et.pdf)

ελληνικά (EL) (174.72 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/el/documents/overview/mabthera-epar-medicine-overview_el.pdf)

français (FR) (138.57 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/fr/documents/overview/mabthera-epar-medicine-overview_fr.pdf)

hrvatski (HR) (161.42 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/hr/documents/overview/mabthera-epar-medicine-overview_hr.pdf)

italiano (IT) (135.97 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/it/documents/overview/mabthera-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.61 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/lv/documents/overview/mabthera-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (159.77 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/lt/documents/overview/mabthera-epar-medicine-overview_lt.pdf)

magyar (HU) (159.45 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/hu/documents/overview/mabthera-epar-medicine-overview_hu.pdf)

Malti (MT) (178.46 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/mt/documents/overview/mabthera-epar-medicine-overview_mt.pdf)

Nederlands (NL) (138.88 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/nl/documents/overview/mabthera-epar-medicine-overview_nl.pdf)

polski (PL) (164.37 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/pl/documents/overview/mabthera-epar-medicine-overview_pl.pdf)

português (PT) (138.09 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/pt/documents/overview/mabthera-epar-medicine-overview_pt.pdf)

română (RO) (159.31 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/ro/documents/overview/mabthera-epar-medicine-overview_ro.pdf)

slovenčina (SK) (162.23 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/sk/documents/overview/mabthera-epar-medicine-overview_sk.pdf)

slovenščina (SL) (161.47 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/sl/documents/overview/mabthera-epar-medicine-overview_sl.pdf)

Suomi (FI) (133.09 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/fi/documents/overview/mabthera-epar-medicine-overview_fi.pdf)

svenska (SV) (135.19 KB - PDF)

**First published:**

30/10/2009

**Last updated:**

11/12/2020

[View](/sv/documents/overview/mabthera-epar-medicine-overview_sv.pdf)

MabThera : EPAR - Risk-management-plan

English (EN) (2.13 MB - PDF)

**First published:** 12/07/2019

**Last updated:** 21/10/2024

[View](/en/documents/rmp-summary/mabthera-epar-risk-management-plan_en.pdf)

## Product information

MabThera : EPAR - Product Information

English (EN) (1.34 MB - PDF)

**First published:** 30/10/2009

**Last updated:** 06/05/2025

[View](/en/documents/product-information/mabthera-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-891)

български (BG) (1.68 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/bg/documents/product-information/mabthera-epar-product-information_bg.pdf)

español (ES) (1.35 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/es/documents/product-information/mabthera-epar-product-information_es.pdf)

čeština (CS) (1.52 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/cs/documents/product-information/mabthera-epar-product-information_cs.pdf)

dansk (DA) (1.18 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/da/documents/product-information/mabthera-epar-product-information_da.pdf)

Deutsch (DE) (1.44 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/de/documents/product-information/mabthera-epar-product-information_de.pdf)

eesti keel (ET) (1.19 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/et/documents/product-information/mabthera-epar-product-information_et.pdf)

ελληνικά (EL) (1.76 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/el/documents/product-information/mabthera-epar-product-information_el.pdf)

français (FR) (1.35 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/fr/documents/product-information/mabthera-epar-product-information_fr.pdf)

hrvatski (HR) (1.33 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/hr/documents/product-information/mabthera-epar-product-information_hr.pdf)

íslenska (IS) (1.19 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/is/documents/product-information/mabthera-epar-product-information_is.pdf)

italiano (IT) (1.37 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/it/documents/product-information/mabthera-epar-product-information_it.pdf)

latviešu valoda (LV) (1.67 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/lv/documents/product-information/mabthera-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.55 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/lt/documents/product-information/mabthera-epar-product-information_lt.pdf)

magyar (HU) (1.51 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/hu/documents/product-information/mabthera-epar-product-information_hu.pdf)

Malti (MT) (1.67 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/mt/documents/product-information/mabthera-epar-product-information_mt.pdf)

Nederlands (NL) (1.26 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/nl/documents/product-information/mabthera-epar-product-information_nl.pdf)

norsk (NO) (1.27 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/no/documents/product-information/mabthera-epar-product-information_no.pdf)

polski (PL) (1.65 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/pl/documents/product-information/mabthera-epar-product-information_pl.pdf)

português (PT) (1.23 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/pt/documents/product-information/mabthera-epar-product-information_pt.pdf)

română (RO) (1.48 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/ro/documents/product-information/mabthera-epar-product-information_ro.pdf)

slovenčina (SK) (1.42 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/sk/documents/product-information/mabthera-epar-product-information_sk.pdf)

slovenščina (SL) (1.39 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/sl/documents/product-information/mabthera-epar-product-information_sl.pdf)

Suomi (FI) (1.26 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/fi/documents/product-information/mabthera-epar-product-information_fi.pdf)

svenska (SV) (1.21 MB - PDF)

**First published:**

30/10/2009

**Last updated:**

06/05/2025

[View](/sv/documents/product-information/mabthera-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000254621 03/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

MabThera : EPAR - All Authorised presentations

English (EN) (19.75 KB - PDF)

**First published:** 29/09/2006

**Last updated:** 10/06/2016

[View](/en/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-530)

български (BG) (77.52 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/bg/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_bg.pdf)

español (ES) (20.36 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/es/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_es.pdf)

čeština (CS) (44.14 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/cs/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (23.63 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/da/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (23.7 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/de/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.63 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/et/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (66.61 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/el/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_el.pdf)

français (FR) (22.14 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/fr/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (39.52 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/hr/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.69 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/is/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.62 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/it/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (29.86 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/lv/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (38.01 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/lt/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (40.42 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/hu/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.63 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/mt/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (23.1 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/nl/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (20.05 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/no/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.93 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/pl/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_pl.pdf)

português (PT) (22.66 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/pt/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_pt.pdf)

română (RO) (72.25 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/ro/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (74.77 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/sk/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.29 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/sl/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.03 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/fi/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.41 KB - PDF)

**First published:**

29/09/2006

**Last updated:**

10/06/2016

[View](/sv/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine MabThera Active substance rituximab International non-proprietary name (INN) or common name rituximab Therapeutic area (MeSH)

- Lymphoma, Non-Hodgkin
- Arthritis, Rheumatoid
- Leukemia, Lymphocytic, Chronic, B-Cell

Anatomical therapeutic chemical (ATC) code L01XC02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

MabThera is indicated in adults for the following indications:

**Non Hodgkin's lymphoma (NHL)**

MabThera is indicated for the treatment of previously untreated adult patients with stage III?IV follicular lymphoma in combination with chemotherapy.

MabThera maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.

MabThera monotherapy is indicated for treatment of adult patients with stage III?IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.

MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non?Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ? 6 months  to &lt; 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).

**Chronic lymphocytic leukaemia (CLL)**

MabThera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including MabThera or patients refractory to previous MabThera plus chemotherapy.

**Rheumatoid arthritis**

MabThera in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease?modifying anti?rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.

MabThera has been shown to reduce the rate of progression of joint damage as measured by X?ray and to improve physical function, when given in combination with methotrexate.

**Granulomatosis with polyangiitis and microscopic polyangiitis**

MabThera, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).

MabThera, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ? 2 to &lt; 18 years old) with severe, active GPA (Wegener's) and MPA.

**Pemphigus vulgaris**

MabThera is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).

## Authorisation details

EMA product number EMEA/H/C/000165 Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1

Opinion adopted 28/01/1998 Marketing authorisation issued 02/06/1998 Revision 63

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

MabThera : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (126.24 KB - PDF)

**First published:** 03/04/2025

**Last updated:** 06/05/2025

[View](/en/documents/procedural-steps-after/mabthera-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

MabThera : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (527.64 KB - PDF)

**First published:** 30/10/2009

**Last updated:** 03/04/2025

[View](/en/documents/procedural-steps-after/mabthera-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

MabThera-H-C-PSUSA-00002652-202211 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/540498/2023

English (EN) (130.64 KB - PDF)

**First published:** 29/11/2023

[View](/en/documents/scientific-conclusion/mabthera-h-c-psusa-00002652-202211-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

MabThera-H-C-PSUSA-00002652-202111 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/592634/2022

English (EN) (117.16 KB - PDF)

**First published:** 31/08/2022

[View](/en/documents/scientific-conclusion/mabthera-h-c-psusa-00002652-202111-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

MabThera-H-C-PSUSA-00002652-202011 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/403185/2021

English (EN) (122.93 KB - PDF)

**First published:** 10/09/2021

[View](/en/documents/scientific-conclusion/mabthera-h-c-psusa-00002652-202011-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

MabThera : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan (II-0168)

Reference Number: EMA/135953/2020

English (EN) (120.08 KB - PDF)

**First published:** 16/03/2020

[View](/en/documents/pip-compliance/mabthera-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan-ii-0168_en.pdf)

MabThera : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan (II-0162)

Reference Number: EMA/135954/2020

English (EN) (120.54 KB - PDF)

**First published:** 16/03/2020

[View](/en/documents/pip-compliance/mabthera-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan-ii-0162_en.pdf)

MabThera-H-C-165-II-0168 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/133144/2020

English (EN) (3.4 MB - PDF)

**First published:** 16/03/2020

[View](/en/documents/variation-report/mabthera-h-c-165-ii-0168-epar-assessment-report-variation_en.pdf)

MabThera-H-C-165-II-0162 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/75432/2020

English (EN) (3.65 MB - PDF)

**First published:** 16/03/2020

[View](/en/documents/variation-report/mabthera-h-c-165-ii-0162-epar-assessment-report-variation_en.pdf)

MabThera-H-C-165-II-149 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/62482/2020

English (EN) (1.39 MB - PDF)

**First published:** 12/02/2020

[View](/en/documents/variation-report/mabthera-h-c-165-ii-149-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for MabThera (II-162)

Adopted

Reference Number: EMA/CHMP/55667/2020

English (EN) (158.61 KB - PDF)

**First published:** 31/01/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-ii-162_en.pdf)

MabThera-H-C-165-II-150 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/206826/2019

English (EN) (1.93 MB - PDF)

**First published:** 12/07/2019

[View](/en/documents/variation-report/mabthera-h-c-165-ii-150-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for MabThera (II-150)

Adopted

Reference Number: EMA/CHMP/47828/2019

English (EN) (71.68 KB - PDF)

**First published:** 01/02/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-ii-150_en.pdf)

CHMP post-authorisation summary of positive opinion for MabThera (II-149)

Adopted

Reference Number: EMA/CHMP/790642/2018

English (EN) (71.67 KB - PDF)

**First published:** 16/11/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-ii-149_en.pdf)

MabThera-H-C-165-X-101-G: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/276108/2016

English (EN) (1.73 MB - PDF)

**First published:** 10/06/2016

**Last updated:** 10/06/2016

[View](/en/documents/variation-report/mabthera-h-c-165-x-101-g-epar-assessment-report-variation_en.pdf)

MabThera-H-C-165-X-83 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/CHMP/71722/2014

English (EN) (1.92 MB - PDF)

**First published:** 06/06/2014

**Last updated:** 06/06/2014

[View](/en/documents/variation-report/mabthera-h-c-165-x-83-epar-assessment-report-extension_en.pdf)

MabThera-H-C-165-II-79 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/462277/2013

English (EN) (1.17 MB - PDF)

**First published:** 24/09/2013

**Last updated:** 24/09/2013

[View](/en/documents/variation-report/mabthera-h-c-165-ii-79-epar-assessment-report-variation_en.pdf)

MabThera-H-C-165-A20-78 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/488088/2013

English (EN) (76.78 KB - PDF)

**First published:** 15/08/2013

**Last updated:** 15/08/2013

[View](/en/documents/variation-report/mabthera-h-c-165-a20-78-epar-assessment-report-article-20_en.pdf)

CHMP post-authorisation summary of positive opinion for MabThera

Adopted

Reference Number: EMA/CHMP/166944/2013

English (EN) (63.57 KB - PDF)

**First published:** 22/03/2013

**Last updated:** 22/03/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera_en.pdf-0)

MabThera-H-C-165-II-69 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/615529/2010

English (EN) (765.87 KB - PDF)

**First published:** 01/12/2010

**Last updated:** 01/12/2010

[View](/en/documents/variation-report/mabthera-h-c-165-ii-69-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for MabThera

Adopted

Reference Number: EMA/598746/2010

English (EN) (119.92 KB - PDF)

**First published:** 24/09/2010

**Last updated:** 24/09/2010

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera_en.pdf)

MabThera-H-C-259-II-64 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/505441/2009

English (EN) (484.83 KB - PDF)

**First published:** 30/10/2009

**Last updated:** 30/10/2009

[View](/en/documents/variation-report/mabthera-h-c-259-ii-64-epar-assessment-report-variation_en.pdf)

MabThera-H-C-259-II-60 : EPAR - Assessment Report - Variation

Reference Number: EMEA/135353/2009

English (EN) (562.7 KB - PDF)

**First published:** 08/04/2009

**Last updated:** 08/04/2009

[View](/en/documents/variation-report/mabthera-h-c-259-ii-60-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Mabthera on 22 January 2009

Adopted

Reference Number: EMEA/CHMP/48585/2009

English (EN) (35.04 KB - PDF)

**First published:** 23/01/2009

**Last updated:** 23/01/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-22-january-2009_en.pdf)

MabThera-H-C-259-II-53 : EPAR - Assessment Report - Variation

English (EN) (147.99 KB - PDF)

**First published:** 10/06/2008

**Last updated:** 10/06/2008

[View](/en/documents/variation-report/mabthera-h-c-259-ii-53-epar-assessment-report-variation_en.pdf)

Committee for medicinal products for human use, post-authorisation summary of positive opinion for Mabthera on 13 December 2007

Reference Number: EMEA/CHMP/572100/2007

English (EN) (32.83 KB - PDF)

**First published:** 20/12/2007

**Last updated:** 20/12/2007

[View](/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-mabthera-13-december-2007_en.pdf)

MabThera : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (525 KB - PDF)

**First published:** 29/09/2006

**Last updated:** 01/03/2024

[View](/en/documents/steps-after-cutoff/mabthera-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

MabThera-H-C-259-II-39 : EPAR - Assessment Report - Variation

English (EN) (189.19 KB - PDF)

**First published:** 29/09/2006

**Last updated:** 29/09/2006

[View](/en/documents/variation-report/mabthera-h-c-259-ii-39-epar-assessment-report-variation_en.pdf)

MabThera-H-C-259-II-44 : EPAR - Assessment Report - Variation

English (EN) (1.53 MB - PDF)

**First published:** 29/09/2006

**Last updated:** 29/09/2006

[View](/en/documents/variation-report/mabthera-h-c-259-ii-44-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

MabThera : EPAR - Scientific Discussion

English (EN) (3.25 MB - PDF)

**First published:** 29/09/2006

**Last updated:** 29/09/2006

[View](/en/documents/scientific-discussion/mabthera-epar-scientific-discussion_en.pdf)

MabThera : EPAR - Procedural steps taken before authorisation

English (EN) (93.09 KB - PDF)

**First published:** 29/09/2006

**Last updated:** 29/09/2006

[View](/en/documents/procedural-steps/mabthera-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on MabThera

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020) 31/01/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019) 01/02/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018) 16/11/2018

[Update on investigation by Italian authorities into the supply of stolen medicines](/en/news/update-investigation-italian-authorities-supply-stolen-medicines) 03/06/2014

[European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection](/en/news/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection) 19/11/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2013) 22/03/2013

[European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations](/en/news/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations) 23/10/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 May 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-may-2012) 25/05/2012

[European Medicines Agency confirms positive benefit-risk balance of MabThera](/en/news/european-medicines-agency-confirms-positive-benefit-risk-balance-mabthera) 25/05/2012

#### More information on MabThera

Questions and answers on the review of MabThera (rituximab)

Reference Number: EMA/CHMP/337123/2012

English (EN) (154.68 KB - PDF)

**First published:** 25/05/2012

**Last updated:** 25/05/2012

[View](/en/documents/medicine-qa/questions-and-answers-review-mabthera-rituximab_en.pdf)

#### More information on MabThera

- [EMEA-000308-PIP01-08-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000308-pip01-08-m04)
- [EMEA-000308-PIP02-11-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000308-pip02-11-m01)
- [RoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/roactemra-hemlibra-herceptin-kadcyla-mabthera-phesgo-tecentriq)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 03/04/2025

## Share this page

[Back to top](#main-content)